Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

By LabMedica International staff writers
Posted on 14 Oct 2025

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most advanced cases eventually recur. More...

Existing monitoring methods fail to distinguish treatment-sensitive from treatment-resistant cell populations, making it hard to predict and prevent relapse. Now, a new method can track the evolution of treatment-resistant cells in ovarian cancer using blood tests, preventing HGSOC from recurring.

The new method, called CloneSeq-SV, developed by researchers at Memorial Sloan Kettering Cancer Center (MSK, New York, NY, USA), combines single-cell whole-genome sequencing with targeted sequencing of structural variants to follow tumor evolution. The method uses structural variants — large DNA rearrangements — as molecular “bar codes” to trace which subclones survive therapy by sampling surgical tumor tissue and serial blood draws. By integrating single-cell and cell-free DNA signals, CloneSeq-SV allows researchers to monitor subpopulation dynamics noninvasively over the course of treatment.

In their study, the team of researchers analyzed longitudinal blood and tissue samples from 18 patients with HGSOC and showed that resistant subpopulations were present at diagnosis and expanded as sensitive cells were eliminated by therapy. Resistant clones carried distinctive features such as oncogene amplifications, chromothripsis, and whole-genome doubling, alterations that explain why they survive standard treatments.

These insights, reported in Nature, create new opportunities to design strategies that target vulnerabilities associated with resistant clones and to match patients to therapies that exploit those weaknesses. For example, one patient’s tumor evolved to be dominated by ERBB2 amplification at recurrence and showed an exceptional response to an ERBB2-targeted drug, illustrating how evolutionary tracking can guide effective second-line therapy. The next steps include studying larger cohorts, collecting richer follow-up samples, and testing the method in other genomically unstable cancers.

“Together, these findings provide new opportunities to develop treatment strategies to attack vulnerabilities associated with those features,” said study first author Marc Williams, PhD, a postdoctoral researcher who uses computational techniques to study cancer evolution.

Related Links:
MSK


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
POC Immunoassay Analyzer
Procise DX
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.